PR Newswire
PLAINSBORO, N.J., May 3, 2017
PLAINSBORO, N.J., May 3, 2017 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its new combination therapy Xultophy® 100/3.6 (insulin degludec and liraglutide injection, 100 units/mL and 3.6 mg/mL) at pharmacies nationwide. Xultophy® 100/3.6 combines long-acting basal insulin Tresiba® (insulin degludec U-100) with the #1 prescribed glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy Victoza® (liraglutide)1 in a single, once-daily injection. Xultophy® 100/3.6 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).2
In clinical studies, Xultophy® 100/3.6 reduced A1C and lowered blood sugar for 24 hours, including before and after meals.2 Xultophy® 100/3.6 can be taken any time of day with or without food.2
"Continuing research and development to find safe and effective medications for people living with diabetes is important, particularly for those who require additional A1C-lowering options," said Dr. Steve Edelman, Founder and Director, Taking Control of Your Diabetes. "Now that Xultophy® 100/3.6 is available, patients with type 2 diabetes who are uncontrolled on basal insulin have a new combination that can help achieve their individualized treatment goals."
Novo Nordisk is working diligently to secure access for Xultophy® 100/3.6 on health plans nationwide. Eligible patients with commercial insurance can use the Xultophy® 100/3.6 Savings Card to reduce co-pays to as little as $1 per day or $30 per month, plus receive a free box of Novo Nordisk needles. Some restrictions apply, for terms and conditions regarding eligibility or benefits of the Xultophy® 100/3.6 (insulin degludec and liraglutide injection, 100 units/mL and 3.6 mg/mL) Savings Card, visit SaveOnXultophy10036.com or call 855-262-5297.
About Xultophy® 100/3.6
Xultophy® 100/3.6 is administered as a once-daily injection from a prefilled pen and can be taken with or without food. Each unit of Xultophy® 100/3.6 contains 1 unit of insulin degludec U-100 and 0.036 mg of liraglutide.2 The starting dose of Xultophy® 100/3.6 is 16 units (16 units insulin degludec and 0.58 mg liraglutide).2 The maximum dose of 50 units of Xultophy® 100/3.6 corresponds to 50 units of insulin degludec and 1.8 mg of liraglutide.2
Kurzfristig positionieren in Novo-Nordisk ADR | ||
HS2GUL
| Ask: 1,89 | Hebel: 5,57 |
mit moderatem Hebel |
Zum Produkt
| |
What is XULTOPHY® 100/3.6?
Xultophy® 100/3.6 is an injectable prescription medicine that contains 2 diabetes medicines, insulin degludec, 100 units/mL, and liraglutide, 3.6 mg/mL. Xultophy® 100/3.6 should be used along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes mellitus when blood sugar levels are not well controlled on: 1) basal insulin (less than 50 units daily) or 2) liraglutide (less than or equal to 1.8 mg daily).
Important Safety Information
What is the most important information I should know about Xultophy® 100/3.6?
Xultophy® 100/3.6 may cause serious side effects, including:
Who should not use Xultophy® 100/3.6? Do not use Xultophy® 100/3.6 if:
What should I tell my health care provider before using Xultophy® 100/3.6 (insulin degludec and liraglutide injection, 100 units/mL and 3.6 mg/mL)?
Tell your health care provider about all your medical conditions, including if you:
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Before using Xultophy® 100/3.6, talk to your health care provider about low blood sugar and how to manage it.
How should I use Xultophy® 100/3.6?
Your dose of Xultophy® 100/3.6 may need to change because of change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or other medicines you take.
What should I avoid while taking Xultophy® 100/3.6?
What are the possible side effects of Xultophy® 100/3.6?
Xultophy® 100/3.6 may cause serious side effects that can be life-threatening, including:
The most common side effects of Xultophy® 100/3.6 may include stuffy or runny nose, sore throat, upper respiratory tract infection, increased blood levels of lipase, nausea, diarrhea, and headache.
Please click here for Xultophy® 100/3.6 Prescribing Information, including Boxed Warning.
About Diabetes
In the United States, more than 29 million people are affected by diabetes.3 Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases.3 Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has quadrupled over the past 30 years.4
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus.
References
Tresiba®, Victoza®, and Xultophy® 100/3.6 are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2017 Novo Nordisk All rights reserved. USA17XUM00843 May 2017
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novo-nordisk-launches-xultophy-10036-insulin-degludec-and-liraglutide-injection-in-the-united-states-300450109.html
SOURCE Novo Nordisk
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.